169 papers found
Refreshing results…
Reducing recombinant protein expression during CHO pool selection enhances frequency of high-producing cells
Impact of N-glycosylation on Fcγ receptor / IgG interactions: unravelling differences with an enhanced surface plasmon resonance biosensor assay based on coiled-coil interactions
Modulating antibody‐dependent cellular cytotoxicity of epidermal growth factor receptor‐specific heavy‐chain antibodies through hinge engineering
Process intensification for the production of rituximab by an inducible CHO cell line
In silico modelling and of monoclonal antibody fed-batch production in CHO cell
Advances in novel vaccines for foot and mouth disease: focus on recombinant empty capsids
Beyond preclinical research: production of CHO-derived biotherapeutics for toxicology and early-phase trials by transient gene expression or stable pools
High-yield production of human Dicer by transfection of human HEK293-EBNA1 cells grown in suspension
Process development for an inducible rituximab-expressing Chinese hamster ovary cell line
Enhanced anti-metastatic bioactivity of an IGF-TRAP re-engineered to improve physicochemical properties
Optimization of a high-cell-density polyethylenimine transfection method for rapid protein production in CHO-EBNA1 cells
Concomitant reduction of lactate and ammonia accumulation in fed-batch cultures: Impact on glycoprotein production and quality
Transient Gene Expression in Suspension HEK293-EBNA1 Cells
A disulfide-stabilized human V L single-domain antibody library is a source of soluble and highly thermostable binders
Combining metabolic and process engineering strategies to improve recombinant glycoprotein production and quality
Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch
Assisted Design of Antibody and Protein Therapeutics (ADAPT)
Abstract 4688: AVID200: a novel computationally-designed TGF beta trap promoting anti-tumor T cell activity
BRAIN DELIVERY OF AN AMYLOID-β OLIGOMER (AβO)-Targeting PEPTIDE-THERAPEUTIC BY a NOVEL BLOOD-BRAIN BARRIER (BBB)-CROSSING DOMAIN ANTIBODY
Preclinical Assessment of Kal-Abp Target Engagement and Efficacy Using Pet, Mri and Csf Biomarkers
Missing publications? Read more about our data sources.